

Composition of commonly used crystalloids

Content	Plasma	Sodium chloride 0.9%*	Sodium chloride 0.18%/ 4% glucose ^a	0.45% NaCl/ 4% glucose ^a	5% glucose ^a	Hartmann's	Lactated Ringer's (USP)	Ringer's acetate	Alternative balanced solutions for resuscitation**	Alternative balanced solutions for maintenance**
Na ⁺ (mmol/l)	135–145	154	31	77	0	131	130	130	140	40
Cl ⁻ (mmol/l)	95–105	154	31	77	0	111	109	112	98	40
[Na ⁺]:[Cl ⁻] ratio	1.28–1.45:1	1:1	1:1	1:1	-	1.18:1	1.19:1	1.16:1	1.43:1	1:1
K ⁺ (mmol/l)	3.5–5.3	*	*	*	*	5	4	5	5	13
HCO ₃ ⁻ / Bicarbonate	24–32	0	0	0	0	29 (lactate)	28 (lactate)	27 (acetate)	27 (acetate) 23 (gluconate)	16 (acetate)
Ca ²⁺ (mmol/l)	2.2–2.6	0	0	0	0	2	1.4	1	0	0
Mg ²⁺ (mmol/l)	0.8–1.2	0		0		0	0	1	1.5	1.5
Glucose (mmol/ l)	3.5–5.5	0	222 (40 g)	222 (40 g)	278 (50 g)	0	0	0	0	0
pH	7.35–7.45	4.5–7.0	4.5		3.5–5.5	5.0–7.0	6–7.5	6–8	4.0–8.0	4.5–7.0
Osmolarity (mOsm/l)	275–295	308	284		278	278	273	276	295	389

* These solutions are available with differing quantities of potassium already added, and the potassium-containing versions are usually more appropriate for meeting maintenance needs.

** Alternative balanced solutions are available commercially under different brand names and composition may vary by preparation.

^a The term dextrose refers to the dextro-rotatory isomer of glucose that can be metabolised and is the only form used in IV fluids. However IV fluid bags are often labelled as glucose so only this term should be used. Traditionally hospitals bought a small range of fluids combining saline (0.18-0.9%) with glucose but several recent NICE/NPSA documents have recommended specific combinations, which are now purchased to enable guidelines to be followed. Glucose–saline combinations now come in 5 different concentrations, and the addition of variable potassium content expands the pre-mixed range to 13 different products. Prescribers must therefore specify the concentration of each component; the term dextrose-saline (or abbreviation D/S) is meaningless without these details. What is specified also impacts significantly on the cost of the product.

Source: This table was drafted based on the consensus decision of the members of the Guideline Development Group.

'Intravenous fluid therapy in adults in hospital', NICE clinical guideline 174 (December 2013)